BioNTech (NasdaqGS:BNTX) has seen a significant price movement in the past week, with its stock rising by 15%, compared to a 2% increase in the broader market. The recent co-development and co ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new ...

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified oncology ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the ...

The transaction is part of BioNTech’s oncology strategy, aimed at expanding the Company’s capabilities to research, develop and commercialize BNT327 as a pan-tumor technology platform for combination ...

Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the ...

MAINZ, Germany, November 4, 2024-- BioNTech SE today reported financial results for the three and nine months ended September 30, 2024 and provided an update on its corporate progress. Ugur Sahin ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of ...

Losses at German drugmaker BioNTech quadrupled in the second quarter from a year earlier, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a ...

BioNTech posted a much bigger-than-expected second-quarter loss Monday as demand for COVID-19 vaccines slid following the ending of the pandemic.

BioNTech: Shares Remain Undervalued Despite Our Lower COVID-19 Vaccine Forecast We assume vaccine demand will remain relatively steady at a trough level going forward.

BioNTech SE is revising plans to build a manufacturing network of vaccine plants in three countries in Africa, just over a year after breaking ground on the first facility in Rwanda.